A study examined the rates of active surveillance use and evaluated the factors associated with selecting this management strategy over surgery or radiation in low-risk prostate cancer, with a focus on underserved Black patients who have been underrepresented in prior studies.Â
The NEST-1 study, which is evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer, both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High CRC (MSI-High), has demonstrated positive results.Â
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
Fred Hutchinson Cancer Center researchers, led by Jonathan Bricker, launched an AI-powered chatbot app called QuitBot to help more people successfully quit smoking cigarettes.Â
FDA approved Balversa (erdafitinib) for adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy.Â
Tempus has added a novel MRD assay, xM, to its testing solutions.Â
Despite the continuing overall decline in cancer death rates—driven by reduction in tobacco use, improvements in early detection, and advances in treatment—the projected number of new diagnoses now tops 2 million for the first time, according to the American Cancer Society’s 2024 Cancer Statistics report.
The American Association for Cancer Research has elected the 2023 class of fellows of the AACR Academy.
Kelly J. Norsworthy was named acting associate director for research mentorship in FDA’s Oncology Center of Excellence.
The Mark Foundation for Cancer Research awarded five new Emerging Leader Awards, totaling $3.75 million, to early-career investigators for projects aimed at addressing unmet needs in cancer research.
